Hitting the Target in HER2-Positive Metastatic Colorectal Cancer
STATEMENT OF NEED
An estimated 153,020 new cases of colorectal cancer (CRC) are diagnosed annually, and 52,550 people die of the disease (Siegel et al, 2023). Approximately 22% of patients present with metastatic disease, which is associated with a dismal 5-year survival rate of 15% (SEER, 2022). Targeting biomarkers is a key strategy for expanding therapeutic options and improving outcomes in metastatic CRC. Human epidermal growth factor receptor 2 (HER2) amplification status and treatment... |
|
Exploring New Treatment Advances for Acid Sphingomyelinase Deficiency in Adults
STATEMENT OF NEED
Acid sphingomyelinase deficiency (ASMD) is a rare, hereditary lysosomal storage disease with multisystemic manifestations, including splenomegaly, hepatomegaly, interstitial lung disease, dyslipidemia, bone marrow and lymph node involvement, and sometimes neurological and peripheral nerve involvement. While the most severe form of ASMD, infantile neurovisceral ASMD, results in death in early childhood, chronic forms of ASMD have more prolonged survival but are associated w... |
|
|
Making the Call in Nonadvanced Systemic Mastocytosis Optimizing Multidisciplinary Management
Series Overview
Nonadvanced systemic mastocytosis (SM) is a group of rare disorders characterized by mast cell accumulation that results in a significant and varied symptomatic burden to the patient. The most prevalent of these symptoms include gastrointestinal symptoms, dermatological symptoms, and recurrent anaphylaxis in response to a variety of triggers such as food, insect venom, and medications. In this Phone-a-Friend series, a multidisciplinary panel of faculty experts will address the... |
|
Answering The Call in Nonadvanced Systemic Mastocytosis
Target Audience
The design of this activity addresses the needs of clinical immunologists/allergists, dermatologists, gastroenterologists, hematologists, and other specialist clinicians who diagnose or manage nonadvanced systemic mastocytosis (SM).
Program Overview
Nonadvanced SM is a challenging disorder to diagnose and manage due to the heterogeneity of symptoms, anaphylactic triggers, and complicated therapeutic paradigm. In this unique and engaging Call-a-Colleague program, a panel of... |
|
Improving Diagnosis and Management of Chronic Idiopathic Constipation Across Diverse Patient Populations
Can you differentiate between chronic idiopathic constipation (CIC) and other conditions characterized by constipation to ensure your patients receive timely and appropriate interventions? Access these educational resources and tools to help you enhance diagnostic processes, management strategies, and multidisciplinary care. Then share this invaluable educational content with your team by using the downloadable discussion guides and slide decks to initiate meaningful conversations. Do you have... |
|
Simple Steps for Improving the Quality of Healthcare for Patients with Chronic Idiopathic Constipation
To ensure your patients with chronic idiopathic constipation (CIC) receive timely, appropriate interventions and the best possible care, clinicians need to better distinguish CIC from similar conditions. In addition, working together, clinicians and patients can make better choices among the many treatment options through shared decision-making (SDM) strategies to help achieve treatment goals.
This digital format provides a brief questionnaire to capture your current practices and delivers... |